An analyst at JPMorgan upgraded shares of Amylin (Nasdaq: AMLN) from Neutral to Overweight today following news that Roche has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE